Moderna Files COVID-19 Vaccine After Second Impressive Read-Out
Does It Have Edge In Preventing Severe Cases?
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
You may also be interested in...
Join us for a brief audio tour around the past week's major biopharma industry developments, as reported by Scrip's global team.
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.